Status:
COMPLETED
A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Tumors
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies
Eligibility Criteria
Inclusion
- Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments.
- Patients who usually have mild symptoms capable of walking and light and sedentary work.
- Patients who can stay in hospital at least during 4 weeks.
Exclusion
- Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.
- Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function.
- Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00613652
Start Date
January 1 2008
End Date
June 1 2009
Last Update
July 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fukuoka, Japan